Dilated Cardiomyopathy
A patient guide to dilated cardiomyopathy, reduced heart function, cause-finding, medicines, devices and family screening.
Dilated cardiomyopathy is characterised by enlargement of one or both ventricles and impaired contraction that is not explained solely by abnormal loading conditions or coronary artery disease. Genetic factors, myocarditis, alcohol, toxins, pregnancy-related disease, persistent tachycardia and systemic illness are among the possible causes.
Assessment
Symptoms may include breathlessness, fatigue, swelling, palpitations or fainting. Evaluation usually includes ECG, echocardiography and blood tests; coronary assessment, cardiac MRI, rhythm monitoring and genetic testing may be appropriate. Finding the cause can change treatment and guide family screening.
Treatment and Monitoring
Guideline-directed heart-failure medicines are introduced and adjusted according to blood pressure, kidney function and potassium. Selected patients may benefit from cardiac resynchronisation therapy or an implantable cardioverter defibrillator after adequate medical treatment and reassessment. Improvement in ejection fraction does not mean follow-up can stop.
Relatives may require ECG and imaging, particularly when a genetic cause or a family history of cardiomyopathy is present.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.